Published in BMC Med on April 24, 2017
Pharmacokinetics of Efavirenz in 2-3 years old children: a high dose of 25 mg/kg per day. Antimicrob Agents Chemother (2017) 0.75
Suboptimal Cotrimoxazole prophylactic concentrations in HIV-infected children according to the WHO guidelines. Br J Clin Pharmacol (2017) 0.75
Virological response and resistances over 12 months among HIV-infected children less than two years receiving first-line lopinavir/ritonavir-based antiretroviral therapy in Cote d'Ivoire and Burkina Faso: the MONOD ANRS 12206 cohort. J Int AIDS Soc (2017) 0.75
Early antiretroviral therapy and mortality among HIV-infected infants. N Engl J Med (2008) 17.12
Mortality of infected and uninfected infants born to HIV-infected mothers in Africa: a pooled analysis. Lancet (2004) 16.28
Trials to assess equivalence: the importance of rigorous methods. BMJ (1996) 9.29
Reporting of noninferiority and equivalence randomized trials: extension of the CONSORT 2010 statement. JAMA (2012) 4.73
Antiretroviral treatment for children with peripartum nevirapine exposure. N Engl J Med (2010) 3.81
Prevalence of resistance to nevirapine in mothers and children after single-dose exposure to prevent vertical transmission of HIV-1: a meta-analysis. Int J Epidemiol (2007) 3.69
Transfer and evaluation of an automated, low-cost real-time reverse transcription-PCR test for diagnosis and monitoring of human immunodeficiency virus type 1 infection in a West African resource-limited setting. J Clin Microbiol (2005) 3.36
Early infant HIV-1 diagnosis programs in resource-limited settings: opportunities for improved outcomes and more cost-effective interventions. BMC Med (2011) 3.08
First-line antiretroviral therapy with a protease inhibitor versus non-nucleoside reverse transcriptase inhibitor and switch at higher versus low viral load in HIV-infected children: an open-label, randomised phase 2/3 trial. Lancet Infect Dis (2011) 3.04
Reuse of nevirapine in exposed HIV-infected children after protease inhibitor-based viral suppression: a randomized controlled trial. JAMA (2010) 2.67
Nevirapine versus ritonavir-boosted lopinavir for HIV-infected children. N Engl J Med (2012) 2.50
Effect of rifampicin on lopinavir pharmacokinetics in HIV-infected children with tuberculosis. J Acquir Immune Defic Syndr (2008) 1.98
Single-dose nevirapine exposure does not affect response to antiretroviral therapy in HIV-infected African children aged below 3 years. AIDS (2015) 1.55
Efavirenz-Based Antiretroviral Therapy Among Nevirapine-Exposed HIV-Infected Children in South Africa: A Randomized Clinical Trial. JAMA (2015) 1.50
Cost-effectiveness of first-line antiretroviral therapy for HIV-infected African children less than 3 years of age. AIDS (2015) 1.49
Is the recommended dose of efavirenz optimal in young West African human immunodeficiency virus-infected children? Antimicrob Agents Chemother (2009) 1.14
Early infant diagnosis of HIV infection in low-income and middle-income countries: does one size fit all? Lancet Infect Dis (2014) 1.10
Initiation of antiretroviral treatment in women after delivery can induce multiclass drug resistance in breastfeeding HIV-infected infants. Clin Infect Dis (2011) 1.07
Missed opportunities for early access to care of HIV-infected infants in Burkina Faso. PLoS One (2014) 0.92
Universal HIV screening at postnatal points of care: which public health approach for early infant diagnosis in Côte d'Ivoire? PLoS One (2013) 0.90
Rethinking the risk-benefit ratio of efavirenz in HIV-infected children. Lancet Infect Dis (2016) 0.84
Missed opportunities of inclusion in a cohort of HIV-infected children to initiate antiretroviral treatment before the age of two in West Africa, 2011 to 2013. J Int AIDS Soc (2016) 0.83
Instability of lopinavir/ritonavir capsules at ambient temperatures in sub-Saharan Africa: relevance to WHO antiretroviral guidelines. AIDS (2005) 0.82
Use of Integrase Inhibitors in HIV-Infected Children and Adolescents. Drugs (2015) 0.79
Antiretroviral treatment in HIV-1 infected pediatric patients: focus on efavirenz. Pediatric Health Med Ther (2014) 0.79
Acceptability of lopinavir/r pellets (minitabs), tablets and syrups in HIV-infected children. Antivir Ther (2016) 0.78
Pharmacokinetics of Efavirenz in 2-3 years old children: a high dose of 25 mg/kg per day. Antimicrob Agents Chemother (2017) 0.75
Suboptimal Cotrimoxazole prophylactic concentrations in HIV-infected children according to the WHO guidelines. Br J Clin Pharmacol (2017) 0.75
Restrictions for reimbursement of interferon-free direct-acting antiviral drugs for HCV infection in Europe. Lancet Gastroenterol Hepatol (2017) 0.75
Virological response and resistances over 12 months among HIV-infected children less than two years receiving first-line lopinavir/ritonavir-based antiretroviral therapy in Cote d'Ivoire and Burkina Faso: the MONOD ANRS 12206 cohort. J Int AIDS Soc (2017) 0.75